Aarti Drugs Limited (IN:AARTIDRUGS)
:AARTIDRUGS
Want to see IN:AARTIDRUGS full AI Analyst Report?
Top Page
Aarti Drugs Limited
(AARTIDRUGS)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹388.00
▼(-4.15% Downside)
Action:ReiteratedDate:11/30/25
Aarti Drugs Limited's overall stock score is influenced primarily by its stable financial performance, despite some challenges in revenue growth and cash flow management. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and oversold conditions. Valuation metrics suggest the stock is fairly valued, but with a low dividend yield. These factors collectively result in a cautious outlook.
Positive Factors
Diversified API & specialty chemicals business
Aarti Drugs sells APIs, pharmaceutical intermediates and specialty chemicals across domestic and international customers. This diversified product and geographic mix reduces single-market dependence, lets the company shift toward higher‑value products, and supports durable revenue stability through industry cycles.
Negative Factors
Declining free cash flow growth
A decline in free cash flow growth and variable operating cash flow reduce internally available capital for capex, deleveraging, or dividends. Persistent FCF weakness can force reliance on external funding, constrain investment in capacity or R&D, and limit resilience to input cost shocks over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified API & specialty chemicals business
Aarti Drugs sells APIs, pharmaceutical intermediates and specialty chemicals across domestic and international customers. This diversified product and geographic mix reduces single-market dependence, lets the company shift toward higher‑value products, and supports durable revenue stability through industry cycles.
Read all positive factors
Aarti Drugs Limited (AARTIDRUGS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹34.23B
Dividend Yield0.24%
Average Volume (3M)11.99K
Price to Earnings (P/E)23.2
Beta (1Y)0.98
Revenue Growth8.22%
EPS Growth33.26%
CountryIN
Employees1,064
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.40
Shares Outstanding91,270,000
10 Day Avg. Volume14,342
30 Day Avg. Volume11,994
Financial Highlights & Ratios
PEG Ratio-16.53
Price to Book (P/B)2.30
Price to Sales (P/S)1.32
P/FCF Ratio46.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹480.00Price Target Upside18.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)24.7
Revenue Forecast (FY)₹29.50B
Aarti Drugs Limited Business Overview & Revenue Model
Company Description
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotect...
How the Company Makes Money
Aarti Drugs primarily makes money by manufacturing and selling (1) APIs, (2) pharmaceutical intermediates, and (3) specialty chemicals to business customers. Revenue is generated through product sales contracts/dispatches to pharmaceutical compani...
Aarti Drugs Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.77B | 23.87B | 25.29B | 27.16B | 24.89B | 21.55B |
| Gross Profit | 9.07B | 8.45B | 8.51B | 3.69B | 3.89B | 6.00B |
| EBITDA | 3.27B | 2.87B | 3.25B | 3.12B | 3.44B | 4.42B |
| Net Income | 1.99B | 1.68B | 1.71B | 1.66B | 2.05B | 2.80B |
Balance Sheet | ||||||
| Total Assets | 26.12B | 25.75B | 24.32B | 24.21B | 22.08B | 17.66B |
| Cash, Cash Equivalents and Short-Term Investments | 245.40M | 226.10M | 89.28M | 211.70M | 343.81M | 219.84M |
| Total Debt | 5.73B | 6.15B | 5.64B | 6.09B | 5.43B | 3.51B |
| Total Liabilities | 11.44B | 12.05B | 11.50B | 12.29B | 11.72B | 8.53B |
| Stockholders Equity | 14.68B | 13.69B | 12.82B | 11.92B | 10.36B | 9.13B |
Cash Flow | ||||||
| Free Cash Flow | 580.50M | 674.20M | 1.33B | -304.70M | -823.39M | 667.19M |
| Operating Cash Flow | 1.52B | 2.45B | 3.59B | 1.34B | 696.36M | 1.55B |
| Investing Cash Flow | -940.60M | -1.65B | -2.24B | -1.64B | -1.49B | -716.79M |
| Financing Cash Flow | -562.20M | -821.20M | -1.36B | 165.40M | 920.25M | -811.29M |
Aarti Drugs Limited Technical Analysis
Neutral
404.80
Price Trends
359.17
Positive
379.32
Negative
435.96
Negative
Market Momentum
2.89
Negative
61.56
Neutral
92.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AARTIDRUGS, the sentiment is Neutral. The current price of 404.8 is above the 20-day moving average (MA) of 347.63, above the 50-day MA of 359.17, and below the 200-day MA of 435.96, indicating a neutral trend. The MACD of 2.89 indicates Negative momentum. The RSI at 61.56 is Neutral, neither overbought nor oversold. The STOCH value of 92.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AARTIDRUGS.
Aarti Drugs Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹807.05B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
73 Outperform | ₹388.40B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
72 Outperform | ₹1.10T | 21.88 | ― | 0.63% | 11.01% | 5.28% | |
68 Neutral | ₹1.06T | 45.14 | ― | 0.87% | 5.08% | -8.91% | |
57 Neutral | ₹34.23B | 23.17 | ― | 0.24% | 8.22% | 33.26% | |
53 Neutral | ₹678.85B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AARTIDRUGS
Aarti Drugs Limited
375.05
28.16
8.12%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,389.55
181.98
15.07%
IN:CIPLA
Cipla Ltd
1,309.90
-199.66
-13.23%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,322.95
147.50
12.55%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,405.55
1,033.27
75.30%
IN:IPCALAB
IPCA Laboratories Limited
1,531.20
154.66
11.24%
Aarti Drugs Limited Corporate Events
Aarti Drugs Injects Rs 10 Crore into Subsidiary Pinnacle Life Science for Expansion
Mar 7, 2026
Aarti Drugs Limited has approved an investment of up to Rs 10 crore in equity shares of its wholly owned subsidiary, Pinnacle Life Science Private Limited, via a rights issue, with shares to be allotted on or before March 20, 2026. The cash infusi...
Aarti Drugs Schedules Investor Meetings at Mumbai Conference
Mar 4, 2026
Aarti Drugs Limited has announced that its officials will participate in an investor conference organized by Investec on March 11, 2026, at Trident BKC in Mumbai, holding one-on-one and group meetings with analysts and institutional investors. The...
Aarti Drugs Deepens Latin American Push with New Chilean Step-Down Subsidiary
Mar 2, 2026
Aarti Drugs Limited has expanded its international footprint in the pharmaceutical sector through the incorporation of Tripharma Chile SpA as an overseas wholly owned subsidiary of its unit Pinnacle Chile SpA, making Tripharma a step-down subsidia...
Aarti Drugs Releases Q3 and 9M FY26 Investor Presentation
Feb 3, 2026
Aarti Drugs Limited has released its investor presentation for the third quarter and nine months of FY26, sharing detailed operational and financial updates with market participants. By making this presentation available to exchanges and investors...
Aarti Drugs Delivers Higher Profit on Modest Revenue Growth, Boosted by Value-Added Segments
Feb 3, 2026
Aarti Drugs Limited reported an 8% year-on-year rise in consolidated revenue to Rs 602.9 crore for the December 2025 quarter, while nine-month FY26 revenue grew 8% to Rs 1,846.6 crore, underscoring steady topline momentum. Despite a 10% YoY declin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.